Share This Author
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction.
- Antonios M. Xydakis, C. Case, C. Ballantyne
- Medicine, BiologyJournal of Clinical Endocrinology and Metabolism
- 1 June 2004
Increases in plasma levels of adiponectin or reductions in TNF-alpha are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss, and there was marked improvement in glucose, insulin, leptin, and triglycerides after 4-6 wk of weight loss.
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
- J. Mckenney, P. Jones, M. Adamczyk, V. Cain, B. Bryzinski, J. Blasetto
- MedicineCurrent Medical Research and Opinion
- 1 January 2003
Analysis showed that more patients in the rosuvastatin 10- to 40-mg groups than in the comparator groups who were at high risk of coronary heart disease according to National Cholesterol Education Program Adult Treatment Panel (ATP) III, Joint European Societies, or Canadian guidelines achieved the LDL-C goals of <100 mg dl−1 (<2.6 mmol l−1).
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
National Lipid Association Annual Summary of Clinical Lipidology 2016.
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
Statins cause modest increases in HDL-C and apo A-I probably mediated by reductions in CETP activity, plausible that such changes independently contribute to the cardiovascular benefits of the statin class but more studies are needed to further explore this possibility.